{"component": "definition", "props": {"groups": [{"size": 4, "snippet_links": [{"key": "the-targets", "type": "clause", "offset": [6, 17]}, {"key": "on-schedule", "type": "definition", "offset": [25, 36]}, {"key": "as-amended", "type": "definition", "offset": [57, 67]}, {"key": "from-time-to-time", "type": "clause", "offset": [68, 85]}, {"key": "in-accordance-with", "type": "definition", "offset": [86, 104]}, {"key": "section-35", "type": "clause", "offset": [105, 116]}], "samples": [{"hash": "i6GIOhJ5Y6r", "uri": "/contracts/i6GIOhJ5Y6r#program-target", "label": "Collaborative Research and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}, {"hash": "gOcEb7krIrG", "uri": "/contracts/gOcEb7krIrG#program-target", "label": "Collaborative Research and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}, {"hash": "e4DV06jqnKT", "uri": "/contracts/e4DV06jqnKT#program-target", "label": "Collaborative Research and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}], "snippet": "means the Targets listed on Schedule 2A attached hereto, as amended from time to time in accordance with Section 3.5.", "hash": "514099e345e5f921fa1fbe4953246e3b", "id": 1}, {"size": 4, "snippet_links": [{"key": "the-research-collaboration", "type": "clause", "offset": [44, 70]}, {"key": "for-purposes-of", "type": "clause", "offset": [72, 87]}, {"key": "the-term", "type": "definition", "offset": [97, 105]}, {"key": "initial-target", "type": "definition", "offset": [140, 154]}, {"key": "with-respect-to", "type": "clause", "offset": [177, 192]}], "samples": [{"hash": "jHT0QKey9ZU", "uri": "/contracts/jHT0QKey9ZU#program-target", "label": "Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)", "score": 25.076659822, "published": true}, {"hash": "bwt6xpH3DpL", "uri": "/contracts/bwt6xpH3DpL#program-target", "label": "Research Collaboration and License Agreement (Dicerna Pharmaceuticals Inc)", "score": 25.0739219713, "published": true}, {"hash": "tUKUZ6tEVb", "uri": "https://investors.dicerna.com/index.php/static-files/468a87e1-3fd6-42cd-b11f-4e697addfe79", "label": "Amendment", "score": 14.015742642, "published": false}], "snippet": "means each Target selected for inclusion in the Research Collaboration. For purposes of clarity, the term Program Target shall mean (a) the Initial Target; (b) any [***] Target with respect to which KHK exercises its [***] Option; (c) [***]; (d) [***]; and (e) [***].", "hash": "3b897ae5759fed1680cac56af1b9ba30", "id": 2}, {"size": 3, "snippet_links": [], "samples": [{"hash": "8XxQElTBgLG", "uri": "/contracts/8XxQElTBgLG#program-target", "label": "License and Collaboration Agreement (Ovid Therapeutics Inc.)", "score": 28.2717316906, "published": true}, {"hash": "7QX0wINzbpz", "uri": "/contracts/7QX0wINzbpz#program-target", "label": "License and Collaboration Agreement (Ovid Therapeutics Inc.)", "score": 28.2142368241, "published": true}, {"hash": "2q6IGzYY5NL", "uri": "http://investors.ovidrx.com/static-files/b343e4ef-c846-44df-b4f0-37d8b6372a3e", "label": "investors.ovidrx.com", "score": 10.1704312115, "published": false}], "snippet": "means Cholesterol 24-hydroxylase (CH24H)[*].", "hash": "ade32a2034dd9301bbca1058c5d98c60", "id": 3}, {"size": 3, "snippet_links": [], "samples": [{"hash": "3O2mWVYwjGs", "uri": "/contracts/3O2mWVYwjGs#program-target", "label": "Option for a License Agreement", "score": 31.340862423, "published": true}, {"hash": "as5YRln7rA4", "uri": "/contracts/as5YRln7rA4#program-target", "label": "Option for a License Agreement (Macrogenics Inc)", "score": 24.7563312799, "published": true}, {"hash": "gwnFq6CKuKM", "uri": "/contracts/gwnFq6CKuKM#program-target", "label": "Option for a License Agreement (Macrogenics Inc)", "score": 24.6741957563, "published": true}], "snippet": "means one or more of the following Targets: (i) CD123, (ii) *** or (iii) gpA33", "hash": "8a0486d5f5df91decd73503313734d02", "id": 4}, {"size": 3, "snippet_links": [{"key": "terminated-target", "type": "definition", "offset": [117, 134]}], "samples": [{"hash": "jxGFifK8dNk", "uri": "/contracts/jxGFifK8dNk#program-target", "label": "Collaboration and License Agreement (Ra Pharmaceuticals, Inc.)", "score": 27.7816563997, "published": true}, {"hash": "8cY3jnSQFUx", "uri": "/contracts/8cY3jnSQFUx#program-target", "label": "Collaboration and License Agreement (Ra Pharmaceuticals, Inc.)", "score": 27.7460643395, "published": true}, {"hash": "ieKIAm2geiY", "uri": "/contracts/ieKIAm2geiY#program-target", "label": "Collaboration and License Agreement (Ra Pharmaceuticals, Inc.)", "score": 27.6255989049, "published": true}], "snippet": "means each of the following protein targets, unless otherwise substituted as provided in Section 2.1(c) or becomes a Terminated Target hereunder: [ *** ].", "hash": "46d9b64da7cf4f46ca0c676c587c91a4", "id": 5}, {"size": 3, "snippet_links": [{"key": "exhibit-b", "type": "clause", "offset": [50, 59]}, {"key": "subject-of", "type": "clause", "offset": [72, 82]}, {"key": "research-plan", "type": "clause", "offset": [95, 108]}], "samples": [{"hash": "dzc5pm6it9Q", "uri": "/contracts/dzc5pm6it9Q#program-target", "label": "Collaboration and License Agreement (Nuvelo Inc)", "score": 21.0, "published": true}, {"hash": "dUOD6hY7zWv", "uri": "/contracts/dUOD6hY7zWv#program-target", "label": "Collaboration and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}, {"hash": "8M3xNwpulhP", "uri": "/contracts/8M3xNwpulhP#program-target", "label": "Collaboration and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}], "snippet": "means a Coagulation Cascade Protein identified in Exhibit B that is the subject of an approved Research Plan.", "hash": "43305b4b82bb9b8955364cd8e3983296", "id": 6}, {"size": 3, "snippet_links": [{"key": "antibody-target", "type": "definition", "offset": [10, 25]}, {"key": "joint-research-committee", "type": "definition", "offset": [91, 115]}, {"key": "the-research-program", "type": "clause", "offset": [156, 176]}, {"key": "relate-to", "type": "definition", "offset": [182, 191]}], "samples": [{"hash": "jGx2a99MfMZ", "uri": "/contracts/jGx2a99MfMZ#program-target", "label": "Collaboration and License Agreement (Immunogen Inc)", "score": 21.0, "published": true}, {"hash": "5RRmD7MoZRs", "uri": "https://investor.immunogen.com/static-files/56daf4ad-71ea-4eb7-8cc7-95132df88727", "label": "investor.immunogen.com", "score": 14.7207131219, "published": false}], "snippet": "means any Antibody Target that is ***** by the ***** as a Program Target and for which the Joint Research Committee has committed to initiate activities in the Research Program that relate to ***** or ***** of ***** against such Target.", "hash": "8d194c2204cebd3bf3737ef7de563de3", "id": 7}, {"size": 3, "snippet_links": [{"key": "joint-research-committee", "type": "definition", "offset": [36, 60]}, {"key": "the-research-program", "type": "clause", "offset": [101, 121]}, {"key": "relate-to", "type": "definition", "offset": [127, 136]}, {"key": "in-vitro", "type": "definition", "offset": [141, 149]}, {"key": "in-vivo", "type": "definition", "offset": [153, 160]}, {"key": "similar-activities", "type": "clause", "offset": [284, 302]}, {"key": "other-activities", "type": "definition", "offset": [334, 350]}, {"key": "related-to", "type": "clause", "offset": [351, 361]}, {"key": "the-target", "type": "clause", "offset": [387, 397]}, {"key": "annual-research-plan", "type": "definition", "offset": [508, 528]}], "samples": [{"hash": "bVDHqT2LwTq", "uri": "/contracts/bVDHqT2LwTq#program-target", "label": "Collaboration and License Agreement (Millennium Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet": "Program Target means [**] which the Joint Research Committee has committed to initiate activities in the Research Program that relate to (a) in vitro or in vivo modulation of the gene corresponding to such target (e.g., through antisense, mouse knockout, etc.), (b) drug discovery or similar activities using such target, or (c) such other activities related to the validation or use of the target in the Inflammation Field as are determined appropriate by the Joint Research Committee and identified in the Annual Research Plan.", "hash": "7c386f1b1395dd4944a5c42d6b4e04e9", "id": 8}, {"size": 2, "snippet_links": [], "samples": [{"hash": "lwJIBbJMp3y", "uri": "/contracts/lwJIBbJMp3y#program-target", "label": "Collaboration Agreement (Exelixis, Inc.)", "score": 28.1567419576, "published": true}, {"hash": "1mLbHn3pZQA", "uri": "/contracts/1mLbHn3pZQA#program-target", "label": "Collaboration Agreement (Exelixis Inc)", "score": 21.0, "published": true}], "snippet": "means MEK.", "hash": "12d685f4bacb9e6bb99ce0f89b157a99", "id": 9}, {"size": 2, "snippet_links": [{"key": "activities-under", "type": "clause", "offset": [50, 66]}, {"key": "section-22", "type": "clause", "offset": [100, 111]}, {"key": "by-the-parties", "type": "clause", "offset": [129, 143]}, {"key": "in-accordance-with", "type": "definition", "offset": [144, 162]}, {"key": "section-23", "type": "clause", "offset": [163, 174]}], "samples": [{"hash": "kvl3fKbtviI", "uri": "/contracts/kvl3fKbtviI#program-target", "label": "Option and License Agreement (Inhibrx, Inc.)", "score": 31.5708418891, "published": true}, {"hash": "2oarimkYnj9", "uri": "/contracts/2oarimkYnj9#program-target", "label": "Option and License Agreement (Inhibrx, Inc.)", "score": 31.4832306639, "published": true}], "snippet": "means a Target that is included as the subject of activities under a given Program, as set forth in Section 2.2 or as determined by the Parties in accordance with Section 2.3.", "hash": "b20c6c7d81def4d2d5dc35eb905cac58", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXcHJvZ3JhbS10YXJnZXQjMDAwMDAwMGEMogECZW4YACAA", "definition": {"size": 70, "title": "Program Target", "snippet": "means the Targets listed on Schedule 2A attached hereto, as amended from time to time in accordance with Section 3.5.", "id": "program-target", "examples": ["By January 1, 2016, the State will provide career development plans, as described in Section VII, for each individual in the Rhode Island Sheltered Workshop and Rhode Island Day <strong>Program Target</strong> Populations.", "Any such second Replacement Target for CytomX may not be a Target that is or was previously a Research <strong>Program Target</strong> of ImmunoGen, and availability of any such second Replacement Target shall be subject to Section 2.1.3 hereof.", "Notwithstanding the foregoing, this Agreement shall terminate as to each Research <strong>Program Target</strong> upon the exercise of the Option with respect to such Research <strong>Program Target</strong>.", "The Parties agree that (a) the Research Programs may benefit from Know-How with respect to the [***] of Targets that Compugen has [***] in the [***] with respect to its [***] Protein Programs (\u201c[***] <strong>Program Target</strong> Know-How\u201d) and (b) Compugen\u2019s [***] respect to the [***] Protein Programs [***] from Program Know-How relating to the [***] of Targets (\u201cResearch <strong>Program Target</strong> Know-How\u201d).", "The Research Program shall be conducted in accordance with the Work Plan for each Research <strong>Program Target</strong> (as more fully provided in Section 2.3 hereof), and each Party shall use its Commercially Reasonable Efforts to perform all activities assigned to it and fulfill all of its obligations under each Work Plan.", "Subject to Sections 2.1.2 and 2.1.3 hereof, CytomX is permitted to include one (1) Research <strong>Program Target</strong> in the Research Program at any given time, and ImmunoGen is permitted to include up to two (2) Research <strong>Program Targets</strong> in the Research Program at any given time.", "ARCHEMIX shall have a period of up to [***] months commencing on the date of receipt of the Designation Notice or a <strong>Program Target</strong> otherwise becomes a Waived Target to notify MERCK that it intends to continue to Develop or Commercialize a Waived Compound.", "In no event will CytomX be required to engage in material activities under a Work Plan for more than one (1) ImmunoGen Research <strong>Program Target</strong> at a time.", "The Parties shall adopt a work plan (each a \u201cWork Plan\u201d) for each Research <strong>Program Target</strong>.", "If CytomX does not provide ImmunoGen with an Option Exercise Notice with respect to its Research <strong>Program Target</strong> during the Term and prior to the CytomX Option Exercise Cut-Off Date, then the applicable Target shall no longer be considered a CytomX Research <strong>Program Target</strong>."], "related": [["collaboration-target", "Collaboration Target", "Collaboration Target"], ["development-candidate", "Development Candidate", "Development Candidate"], ["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["product-candidate", "Product Candidate", "Product Candidate"], ["soft-target", "Soft Target", "Soft Target"]], "related_snippets": [], "updated": "2025-07-06T21:56:50+00:00"}, "json": true, "cursor": ""}}